Core Viewpoint - Meili Tianyuan Medical Health Industry Co., Ltd. is positioning itself as a key player in the high-end beauty market, observing consumer trends through its extensive network of stores in major cities [1] Group 1: Super Brand Strategy - The beauty service industry is highly fragmented, with many regional and small brands lacking influence and consumer trust [2] - Differentiation through branding is essential for success in a mature and competitive market [3] - Meili Tianyuan's acquisition of 100% of Siyuanli for 1.25 billion yuan positions it among the top three beauty brands in China, alongside its existing brand Nairui [3] - National brand stores have a 2.1 times higher consumer recharge willingness compared to small brands, with an average recharge amount 60% higher [3] - Enhancing brand awareness can increase customer spending by 20% to 50% for each level of recognition [3] - The company aims to redefine customer experience by focusing on sensory engagement and establishing industry standards [4] Group 2: Super Chain Strategy - The beauty industry is characterized by a high degree of market fragmentation, with 89% of beauty institutions being single stores [5] - Meili Tianyuan's business model focuses on "Double Beauty + Double Health," aiming to create sustainable growth through both internal and external strategies [5] - The company currently has nine cities generating over 100 million yuan in revenue and plans to expand this to 20 core cities [5] - Supply chain capabilities are crucial for chain enterprises, and Meili Tianyuan will enhance partnerships with quality suppliers to offer high-quality products at better prices [5] Group 3: Super Digitalization Strategy - Many beauty service providers still rely on manual record-keeping, which limits data integration and business empowerment [7] - Digitalization is viewed as a critical tool for future decision-making, shifting from traditional customer acquisition to precise online targeting [7] - The company has invested over 200 million yuan in the past five years to build a 90-member IT team, focusing on digital integration across all operations [7] - Meili Tianyuan categorizes over 200 customer attributes and launches more than 2,000 targeted marketing campaigns annually, achieving double-digit growth in new memberships [8] - The company aims to leverage medical beauty resources and digital supply chain capabilities to create a transformative effect in the industry [8]

Core Insights - The company, Meili Tianyuan, announced three major strategic upgrades: Super Brand, Super Chain, and Super Digitalization, aiming to redefine high-end beauty services and reshape the industry's value space [1][18]. Super Brand - The beauty service industry is highly fragmented, with many regional and small brands lacking influence, leading to high consumer trust costs and low loyalty [4]. - Brand differentiation is crucial for standing out in a saturated market, as evidenced by data showing that consumers are 2.1 times more willing to recharge at national brands compared to smaller ones, with average recharge amounts being 60% higher [4]. - Meili Tianyuan's Super Brand strategy leverages its position as the umbrella for the top three brands in China's beauty industry, aiming to enhance customer experience and brand recognition [4][5]. Super Chain - The beauty industry is characterized by a high degree of fragmentation, with 89% of beauty institutions being single stores [8]. - The low entry barriers and lack of economies of scale hinder the growth of larger chains [8]. - Meili Tianyuan's Super Chain strategy focuses on creating 20 "1 billion revenue Clubs" in key cities, building on its existing nine cities with over 1 billion in revenue [8][9]. Super Digitalization - Many beauty service providers still rely on manual processes, with digitalization seen as essential for future decision-making and customer service enhancement [12]. - Meili Tianyuan has invested over 200 million in digitalization over the past five years, establishing a 90-member IT team to integrate digital solutions across its operations [12][13]. - The company has developed over 200 customer attribute classifications and maintains a member retention rate of 80%, with customer acquisition costs remaining below 2% [12][13]. Acquisition of Siyuanli - The acquisition of Siyuanli is viewed as a strategic move to consolidate the top three brands in the high-end beauty sector under Meili Tianyuan, following the successful integration of the second-largest brand, Nairui [15][16]. - The structural similarities and customer overlap between Meili Tianyuan and Siyuanli provide a strong foundation for synergy and enhanced resource utilization [16]. Industry Outlook - The beauty and health sector is positioned for significant growth, driven by consumer demand for self-care and wellness, with Meili Tianyuan leading the charge with its strategic initiatives [18].

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced a share transfer agreement to acquire 100% equity of medical businesses in Dongguan and Zhuhai for a total consideration of RMB 40 million (approximately HKD 44 million) [1] Group 1: Acquisition Details - The buyer, a non-wholly owned subsidiary of the company, will acquire 90% equity of the target company upon completion of the acquisition [1] - The acquisition will lead to the addition of 19 new direct-operated stores, including 2 medical beauty stores and 17 lifestyle beauty stores, expanding the company's direct store scale [1] - The acquisition is expected to enhance the company's revenue significantly and deepen its market penetration in core cities of the Greater Bay Area [1] Group 2: Target Business Operations - The medical targets in Dongguan and Zhuhai are operated by Guangzhou Nairui Health Medical Investment Co., Ltd., focusing on medical outpatient services [1] - The Zhuhai target, Zhuhai Nairui Naimei Beauty Technology Co., Ltd., operates 8 Nairui brand beauty and health service stores [1] - The Dongguan target, Nairui Beauty Chain (Dongguan) Co., Ltd., operates 9 Nairui brand beauty and health service stores [1]

Core Insights - New Oxygen (SY.US) reported Q3 revenue of $54.3 million, a 4.0% year-over-year increase, exceeding market expectations; the company recorded a loss of $0.09 per share [1] - Revenue from beauty treatment services surged 304.6% year-over-year to RMB 183.6 million ($25.8 million), surpassing guidance [1] - The number of verified treatment visits at brand beauty centers exceeded 89,800 in Q3, compared to approximately 23,600 in the same period last year [1] Financial Performance - Active users visiting brand beauty centers over the 12 months ending September 30, 2025, exceeded 130,000, up from about 30,300 year-over-year [1] - The number of core users increased by over 10,000 in the quarter, achieving a 40% quarter-over-quarter growth; these core members contributed 88% of beauty care service revenue with a quarterly repurchase rate of approximately 70% [1] - As of September 30, 2025, total cash and cash equivalents, restricted cash, time deposits, and short-term investments amounted to RMB 942.8 million (approximately $132.4 million), down from RMB 1.2532 billion as of December 31, 2024, primarily due to increased investments in brand beauty centers [1] Future Outlook - For Q4 2025, New Oxygen expects revenue from beauty care services to be between RMB 216 million (approximately $30.3 million) and RMB 226 million (approximately $31.7 million), representing a year-over-year growth of 165.8% to 178.1% [2]

Group 1: Market Strategy and Economic Outlook - The report indicates that the Hong Kong stock market is poised for a rebound, driven by the easing of US dollar liquidity, which is expected to benefit major asset classes [5][8][9] - The report recommends an overweight position in Hong Kong stocks, A-shares, and commodities, while maintaining a neutral position in Chinese bonds and increasing exposure to US stocks and bonds [9] Group 2: Transportation Industry Insights - The express delivery sector is anticipated to benefit from anti-involution policies, with prices starting to rise since September 2025, indicating a positive trend for future growth [11] - The oil shipping industry faces challenges due to an aging fleet, with the average age of large oil tankers reaching a historical high of 13 years, while new orders are insufficient to meet future capacity needs [12] - The aviation sector is expected to enter a supply-demand resonance cycle, with a low growth rate in aircraft supply and a positive outlook for passenger volume growth in 2025 [13] Group 3: Construction and Building Materials Sector - The construction and building materials industry is at a bottoming phase, with a need for transformation due to insufficient domestic demand and increasing uncertainties from overseas [2][15] - The report highlights the importance of mergers and restructuring among state-owned enterprises to address excess capacity in the construction sector [2] - Recommendations include focusing on major construction blue-chip stocks and international engineering firms, as well as domestic cyclical stocks that are expected to benefit from demand recovery [2] Group 4: Macro Financial Data - In October, loan growth slowed, with new loans amounting to 220 billion yuan, significantly lower than the previous year's 500 billion yuan, reflecting ongoing challenges in the real estate market [18] - The report notes a decrease in social financing growth, with new social financing at 814.9 billion yuan, down from 1.41 trillion yuan in the previous year [19] - The M1 and M2 money supply growth rates have also declined, indicating tighter liquidity conditions [19] Group 5: Company-Specific Developments - Meili Tianyuan Medical Health's acquisition of Siyuanli for 1.25 billion yuan is expected to solidify its position as a leader in the high-end beauty sector, with the integration projected to enhance overall performance [21][22] - The report anticipates that the acquisition will lead to a significant increase in the number of active members and improve operational efficiency through resource synergies [22][23] - The company plans to utilize 1.2 billion HKD for dividends and buybacks over the next three years, highlighting its commitment to shareholder returns [23]

Core Viewpoint - Meili Tianyuan Medical Health (02373) is positioned as a leading enterprise in the domestic beauty and medical beauty service sector, with strong brand reputation and operational capabilities. The company is expected to see performance growth driven by deepening digital transformation, improved industry chain layout, and store expansion [1] Group 1: Acquisition Details - In October 2025, Meili Tianyuan announced plans to acquire 100% equity of Shanghai Siyuanli Industrial Co., Ltd. for a consideration of 1.25 billion RMB. Siyuanli is the third-largest beauty service brand in China, projected to achieve revenue of 850 million RMB and net profit of 81 million RMB in 2024 [1][2] - The acquisition follows Meili Tianyuan's previous acquisition of the second-largest beauty service brand, Nairui'er, in 2024, marking another significant acquisition [1] Group 2: Financial Metrics and Valuation - The acquisition is valued at 17.2X PE based on Siyuanli's projected net profit of 72.675 million RMB for the period from July 1, 2024, to June 30, 2025, which is significantly lower than Meili Tianyuan's current PE of approximately 29.2X and the industry average of 21.1X [3] - The payment structure includes 325 million RMB in cash, 510 million RMB in acquisition loans, and 415 million RMB in share payments, with the deal expected to close in December 2025 and be consolidated in January 2026 [3] - Post-acquisition, the expected EPS is projected to increase from 1.36 RMB to 1.62 RMB, representing an 18% enhancement [3] Group 3: Market Position and Synergy - The acquisition will consolidate Meili Tianyuan, Nairui'er, and Siyuanli as the top three players in the Chinese beauty service industry, with a total of over 734 stores and a market coverage of 42%, significantly enhancing the company's market influence [4] - The integration of Nairui'er’s operational experience is expected to enhance Siyuanli's efficiency through scale procurement, joint product development, and exclusive customization, potentially improving both gross and net profit margins [4]

Core Viewpoint - Meili Tianyuan Medical Health (02373) is positioned as a leading enterprise in the domestic beauty and medical beauty service sector, with strong brand reputation and operational capabilities. The company is expected to see significant performance growth due to deepening digital transformation, improved industry chain layout, and ongoing store expansion [1]. Group 1: Financial Projections - The projected net profit for Meili Tianyuan from 2025 to 2027 is estimated to be 337 million, 458 million, and 588 million RMB respectively, with previous estimates adjusted due to the acquisition's expected contribution [1]. - The current stock price corresponds to a price-to-earnings (PE) ratio of 20.4, 15.0, and 11.7 for the years 2025, 2026, and 2027 respectively, with a target price set at 42.64 HKD based on a 20x PE for 2026 [1]. Group 2: Acquisition Details - Meili Tianyuan plans to acquire 100% of Shanghai Siyuanli Industrial Co., Ltd. for a total consideration of 1.25 billion RMB, marking a significant acquisition following the purchase of the second-largest beauty service brand, Nairui'er [2]. - Siyuanli is recognized as the third-largest beauty service brand in China, with projected revenues of 850 million RMB and a net profit of 81 million RMB for 2024 [2]. Group 3: Operational Insights - As of June 30, 2025, Siyuanli operates 163 high-end beauty service stores and 19 medical beauty clinics across 48 cities, with over 90% of its revenue generated from first-tier and new first-tier cities [3]. - The acquisition is expected to increase Meili Tianyuan's active direct member base by 44%, enhancing its "dual beauty + dual healthcare" business model [3]. Group 4: Transaction Highlights - The acquisition is valued at a PE ratio of 17.2, significantly lower than Meili Tianyuan's current PE of approximately 29.2 and the industry average of 21.1 [4]. - The payment structure includes 325 million RMB in cash, 510 million RMB in acquisition loans, and 415 million RMB in share payments, with the deal expected to close in December 2025 [4]. Group 5: Strategic Positioning - Post-acquisition, Meili Tianyuan, Nairui'er, and Siyuanli will collectively dominate the top three positions in China's beauty service industry, with over 734 stores and a market coverage of 42% [5]. - The integration of Nairui'er’s operational experience is anticipated to enhance Siyuanli's efficiency and profitability through supply chain collaboration and digital transformation efforts [5].

Core Viewpoint - The acquisition of Siyanli by Meili Tianyuan Medical Health (02373) is expected to solidify its position in the mid-to-high-end beauty care services market, with potential for further optimization in its business model through both organic and external growth strategies [1][2] Group 1: Acquisition Details - The company announced on October 15 that it will acquire 100% equity of Siyanli, the third-largest beauty service brand in China, for a consideration of 1.25 billion RMB [1] - Siyanli operates 163 beauty service stores and 19 medical beauty clinics across 48 cities in China, with approximately 60,000 active members [2] - The acquisition is expected to enhance the company's overall competitiveness and leverage synergies, as it will consolidate the top three beauty service brands in the country [2] Group 2: Financial Projections - The company updated its net profit forecasts for 2025-2027 to 372 million, 409 million, and 486 million RMB, respectively, with corresponding P/E ratios of 18X, 17X, and 14X [1] - Siyanli is projected to achieve a net profit of 81 million RMB in 2024, with expectations of improving its profit margin from 6.5% in 2023 to 10.4% by the first half of 2025 after integration [2] - The acquisition price corresponds to a TTM P/E valuation of approximately 17 times, which is lower than the valuation of the listed company [2] Group 3: Shareholder Returns - The company plans to maintain a dividend payout of no less than 50% of the net profit attributable to shareholders for the next three complete financial years [1][2] - The company has been actively repurchasing shares to support its market price, having repurchased 605,500 shares out of an authorized 23.58 million shares [2]

Core Viewpoint - The acquisition of Siyuanli by Meili Tianyuan Medical Health is expected to strengthen its position in the mid-to-high-end beauty care service market, with potential for further optimization in its business model through both organic and external growth strategies [1][2]. Group 1: Acquisition Details - The company announced the acquisition of 100% equity of Siyuanli for a consideration of 1.25 billion RMB [1]. - Siyuanli is the third-largest beauty service brand in China, with projected revenue of 849 million RMB in 2024 and operations in 48 cities with 163 beauty stores and 19 medical beauty clinics [2]. - The acquisition will consolidate the company’s competitive position by bringing together the top three beauty service brands and capturing 42% of high-end commercial properties in first- and second-tier cities [2]. Group 2: Financial Projections - The company updated its net profit forecasts for 2025-2027 to 372 million, 409 million, and 486 million RMB, respectively, with corresponding PE ratios of 18X, 17X, and 14X [1]. - Siyuanli is expected to achieve a net profit of 81 million RMB in 2024, with potential for profit margin improvement similar to the company’s previous acquisition of Nairui, which saw an increase from 6.5% in 2023 to 10.4% in the first half of 2025 [2]. Group 3: Shareholder Returns - The company plans to maintain a dividend payout of no less than 50% of the net profit attributable to shareholders for the next three complete financial years [1][2]. - The company has been actively repurchasing shares, having bought back 605,500 shares out of an authorized 23.58 million shares, to support its market price [2].

Core Viewpoint - The acquisition of Siyuanli is expected to significantly enhance the company's performance, leading to an upward revision of the net profit forecasts for 2025-2027 [1] Group 1: Financial Performance and Projections - The revised net profit estimates for Meili Tianyuan Medical Health (02373) are 320 million, 440 million, and 490 million RMB for 2025, 2026, and 2027 respectively, reflecting increases of 5%, 26%, and 21% [1] - Corresponding EPS for the same years are projected to be 1.36, 1.86, and 2.09 RMB, with current PE ratios of 20, 14, and 13 times [1] Group 2: Shareholder Return Plan - The company announced a long-term shareholder return plan, aiming to utilize up to 1.2 billion HKD over the next three years [2] - The return plan will be executed through two main methods: annual dividends of no less than 50% of the company's net profit and ongoing share buybacks [3] Group 3: Acquisition of Siyuanli - The company announced a strategic acquisition of 100% of Siyuanli for 1.25 billion RMB, which is the third-largest beauty service brand in China [4] - Following the acquisition, approximately 60,000 active members from Siyuanli will be integrated into the company's membership system, increasing the active membership base by over 44% [4] - The acquisition is expected to significantly enhance the company's market share in high-tier cities, solidifying its position as an industry leader [4] Group 4: Growth Strategy - The company employs a "dual growth" strategy, combining organic growth with acquisitions, which has successfully built a high-quality membership system [5] - The successful integration of the second-largest brand, Nairui, has demonstrated the company's capability in synergistic integration, with Nairui's net profit margin increasing from 6.5% to 10.4% post-acquisition [5] - The company anticipates that the acquisition of Siyuanli will further enhance operational efficiency and strengthen the competitive position of both Siyuanli and Meili Tianyuan brands [5]